Influx Healthtech Ltd(INFLUX)

NSE: INFLUX

₹ 257-0.43%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 595 crUpdated: 24 Oct 2026

About

Influx Healthtech is a contract development and manufacturing (CDMO) company that makes nutraceuticals, cosmetics, ayurvedic, veterinary and homecare products. Nutraceuticals made up about 89.83% of revenue in FY26. Reported revenue for FY26 was 146.83 (Rs Cr). The company says it has a presence across four continents.^[1][2]

Business segments

Nutraceuticals contributed about 89.83% of revenue in FY26.^[1]
Other segments' share of FY26 revenue: cosmetics 5.06%, ayurvedic 4.17%, veterinary 0.91%, homecare 0.03%.^[1]
In FY26 the company set up OLAHEY Wellness Pvt Ltd, a wholly owned subsidiary for beverages and healthy snacking, its move into consumer (B2C) brands.^[3]

Products and formats

Had a portfolio of more than 3,400 SKUs in Q1 FY27.^[4]
Specialty formats in Q4 FY26 included liposomal delivery, MMTC (multi mini tablet in capsule), capsule-in-capsule and pellet technologies.^[3]
Launches in Q3 FY26 included high-calorie nutritional pastes, vegan protein water and colour-changing sunscreens.^[5]
The company plans to expand into medical nutrition (GLP-1 support) and sports nutrition, according to the Q3 FY26 call.^[5]

Operations and approvals

Products are made in GMP, HACCP, ISO 22000, Halal and US FDA registered facilities, according to the FY26 annual report.^[1]
Commissioned a new tablet granulation line in Q1 FY27 that processes about 480 kg/day, enough for roughly 24,000 bottles per day.^[4]
Utilisation rose across the nutraceutical, cosmetic and veterinary manufacturing lines in Q4 FY26.^[3]
Equipment commissioned or installed in Q4 FY26: a Quick Snap machine, a liquid gel sachet machine, a 3-track blister machine and auto powder filling.^[3]
The company reported nil R&D expenditure for FY26.^[1]

Customers and exports

Avolt Brand made a long-term commitment for about 24 lakh protein bars (Q4 FY26).^[3]
Long-standing clients placed repeat orders in Q4 FY26, and the company kept onboarding D2C wellness brands and clinical nutrition startups.^[3]
The FY26 annual report lists a limited client base and heavy reliance on nutraceuticals among the company's risks.^[1]
The company cleared a Tanzania regulatory audit in Q4 FY26. As of Q1 FY27, customer product registrations are progressing for Tanzania, Nigeria, Kenya and other markets.^[3][4]

Expansion and capex

Rs 10 Cr was reallocated to grow the nutraceutical CDMO facility from about 35,000 to 75,000 sq ft. It is expected to start running by August 2026, giving about 2.5x capacity.^[4]
Pet nutrition capacity is rising from 16-18 to 25 tonnes/month. The extrusion line ordered takes processing from 100-150 kg/hr to 1,000 kg/hr (Q1 FY27).^[4]
Factory acceptance testing of the 1,000 kg/hr pet food line was completed in Q4 FY26, and an additional bar line has been booked.^[3]
The company is building beverage canning, carbonated and Tetra Pak lines with 10,000 bottles/hour capacity (Q1 FY27).^[4]
IPO funds set aside for manufacturing facilities: Rs 3,673.34 lakh, of which 1,384.15 lakh was used and 2,289.19 lakh was unused at the end of FY26.^[1]

Company guidance

For FY27, the company guided topline growth of about 25-30% and an EBITDA margin of about 20-22% (Q1 FY27 call).^[4]

Recent developments

On 23 Sep 2026, NSE fined the company Rs 1,82,900 including GST. The fine was for filing half-yearly consolidated results for the period ended 31 Mar 2026 late, under SEBI LODR Regulation 33.^[6]
The IPO was priced at Rs 96 per equity share, according to the FY26 annual report.^[1]

Market Cap

₹595 Cr

High / Low

₹315 / 169

Stock P/E

29.8

Price / Book

0.0

Book Value

₹44

EPS

₹8.9

No. of Shares

2.32 Cr

ROCE

27.2%

ROE

20.4%

OPM

18.5%

Debt / Equity

0.00

Sales

₹147 Cr

Net Profit

₹21 Cr

Promoter holding

73.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials